Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-04-22
2008-04-22
Campell, Bruce (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S202100, C424S192100, C424S184100
Reexamination Certificate
active
11450729
ABSTRACT:
Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.
REFERENCES:
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4520113 (1985-05-01), Gallo et al.
patent: 4551270 (1985-11-01), Danos et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4748109 (1988-05-01), Baird
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4983728 (1991-01-01), Herzog et al.
patent: 5039607 (1991-08-01), Skold et al.
patent: 5045447 (1991-09-01), Minson
patent: 5057411 (1991-10-01), Lancaster et al.
patent: 5071757 (1991-12-01), Kreider et al.
patent: 5081029 (1992-01-01), Zarling et al.
patent: 5180806 (1993-01-01), Dillner et al.
patent: 5186933 (1993-02-01), Estes
patent: 5437951 (1995-08-01), Lowy et al.
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5709996 (1998-01-01), Lowy et al.
patent: 5716620 (1998-02-01), Lowy et al.
patent: 5744142 (1998-04-01), Lowy et al.
patent: 5756284 (1998-05-01), Lowy et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 5871998 (1999-02-01), Lowy et al.
patent: 5874089 (1999-02-01), Schlegel et al.
patent: 5888516 (1999-03-01), Jansen et al.
patent: 5985610 (1999-11-01), Lowy et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6485728 (2002-11-01), Schlegel et al.
patent: 2003/0219873 (2003-11-01), Lowy et al.
patent: 2005/0100556 (2005-05-01), Lowy et al.
patent: 0 133 123 (1985-02-01), None
patent: 0 256 321 (1988-02-01), None
patent: 0 343 783 (1989-11-01), None
patent: 0 390 252 (1990-10-01), None
patent: 0 451 550 (1991-10-01), None
patent: WO 90/10459 (1990-09-01), None
patent: WO 90/10867 (1990-09-01), None
patent: WO 91/04330 (1991-04-01), None
patent: WO 91/18118 (1991-11-01), None
patent: WO 91/18294 (1991-11-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 94/00152 (1994-01-01), None
patent: WO 94/20137 (1994-09-01), None
patent: WO 99/01557 (1999-01-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 03/001208 (2003-01-01), None
Alberts et al. eds. (1989)Molecular Biology of the Cell, 2nd ed. Garland Publishing, New York. Chapter 3 p. 87-134.
Alberts et al. eds. (1989)Molecular Biology of the Cell, 2nd ed. Garland Publishing, New York. p. 135, 169-171.
Alberts et al. eds. (1989)Molecular Biology of the Cell, 2nd ed. Garland Publishing, New York. p. 265.
Alberts et al. eds. (1989)Molecular Biology of the Cell, 2nd ed. Garland Publishing, New York. p. 269-70.
Alberts et al. eds. (1989)Molecular Biology of the Cell, 2nd ed. Garland Publishing, New York. Chapter 18 p. 1001-1057.
AF Geijersstam et al. (1999) “A Survey of Seroprevalence of Human Papillomavirus Types 16, 18 and 33 among Children”,Int. J. Cancer80: 489-493.
Anderson-Ellstrom et al. (1996) “Comparison of Development of Serum Antibodies to HPV16 and HPV33 and Acquisition of Cervical HPV DNA Among Sexually Experienced and Virginal Young Girls”.Sex. Transm. Dis. 23: 234-238.
Andrews et al. (1978) “Reovirus” inViruses of Vertebrates, third edition. Bailliere Tyndall London p. 57-60.
Antinore et al. (1991) “HPV-16 E7 is Cytotoxic when Expressed from the CMV Promoter in the SCC 12 F.2 Line”. Abstract.Papillomavirus Workshop. Jul. 20 to Jul. 26. Seattle, Washington.
ASV Scientific Program, (1990) The American Society for Virology 1990 Annual Meeting, Jul. 8-12, 1990.
Bachmann et al. (1997) “Neutralizing Antiviral B Cell Responses”,Annual Rev. Immunol., 15:235-270.
Baker (1987) “Sequence Analysis of Papillomavirus Genomes”, inThe Papovaviridae, Plenum Press, New York, pp. 321-385.
Baker et al. (1991) “Structures of Bovine and Human Papillomaviruses, Analysis by cryoelectron microscopy and three-dimensional image reconstruction”,Biophys. J. 60:1445-1456.
Balsley et al. (2000) “Progress in the Development of Human Papillomavirus Vacccines for HPV-11 and HPV-16/18 and Mapping of a Critical Neutralizing Epitope”,18thInternational Papillomavirus Conference2000 (Abstract).
Band et al. (1990) “Human Papilloma Virus DNAs Immortalize Normal Human Mammary Epithelial Cells and Reduce their Growth Factor Requirements”,PNAS USA87: 463-467.
Becker et al. (2004) “Nuclear localization but Not PML Protein Is Required for Incorporation of the Papillomavirus Minor Capsid Protein L2 into Virus-like Particles”,J. of Virol. 78: 1121-1128.
Beiss et al. (1991) “Type-Specific and Cross-Reactive Epitopes in Human Papillomavirus Type 16 Capsid Proteins”,Virology184:460-464.
Belnap et al. (1996) “Conserved Feature in Papillomavirus and Polyomavirus Capsids”,J. Molecular Biology259: 249-263.
Bernard et al. (1994) “Evolution of Papillomaviruses”,Curr. Top. Micro. and Immuno. 186:33-54.
Bertioli et al. (1991) “Transgenic Plants and Insect Cells Expressing the Coat Protein of Arabis Mosaic Virus Produce Empty Virus-Like Particles”,J. Gen. Virol. 72:1801-1809.
Bierly et al. (1992) “Morphometric Estimation of Viral Burden in Cell Culture Material by Transformation Electron Microscopy (TEM)”,Proc. of 50th Annual Meeting of Electron Microscopy Society of America. p. 732-733.
Big Dye Terminator v3.1 Cycle Sequencing Kit Protocol by Applied Biosystems (2002) Chapter 3 and table of contents.
Bjørge et al. (1997) “A Prospective, Seroepidemiological Study of the Role of Human Papillomavirus in Esophageal Cancer in Norway”,Cancer Res. 57: 3989-3992.
Bjørge et al. (1997) “Prospective Seroepidemiological Study of Role of Human Papillomavirus in Non-Cervical Anogenital Cancers.”,BMJ315: 646-649.
Bonnez et al. (1990) “Neutralization of HPV-11 Infection by Specific Polyclonal Antiserum Directed Against HPV-11 Viral Particles”, Abstract at thePapillomavirus Workshop, Heidelberg, Germany May 12-17, 1990.
Bonnez et al. (1990) “Use of HPV-11 Viral Particles in an Elisa to Detect Antibodies (Ab) in Humans with or without Condylomata Acuminata (CA)”, Abstract at thePapillomavirus Workshop, Heidelberg, Germany May 12-17, 1990.
Bonnez et al. (1990) “The Pstl-Xholl Restriction Fragment of the HPV-6b L1 ORF Lacks Immunilogical Specificity as Determined by Sera From HPv6 Condyloma Acuminatum Patients and Controls,”Papillomavirusesp. 77-80.
Bonnez et al. (1991) “Antibody (Ab) Response to HPV-11 in Children with Juvenile-Onset Recurrent Respiratory Papillomatosis (RRP),” Abstract.1991 Papillomavirus Workshop. Jul. 20 to Jul. 26. Seattle, Washington.
Bonnez et al. (1991) “Neutralization of HPV-11 Infection in the Nude Mouse Xenograft Model with an Antibody Directed to a 15-mer Peptide Derived from the 3′ End of HPV-11 L1 ORF”,1991 Papillomavirus Workshop. Jul. 20 to Jul. 26. Seattle, Washington.
Bonnez et al. (1991) “Use of Human Papillomavirus Type 11 Virions in an ELISA to Detect Specific Antibodies in Humans with Condylomata Acuminata”,J. Gen. Virol. 72:1343-47.
Bonnez et al. (1992) “Antibody Response to Human Papillomavirus (HPV) Type 11 in Children with Juvenile-Onset Recurrent Respiratory Papillomatosis (RRP)”,Virology188:384-387.
Bonnez et al. (1992) “Antibody-Mediated Neutralization of Human Papillomavirus Type 11 (HPV-11) Infection in the Nude Mouse: Detection of HPV-11 mRNAs”,J. Infectious Diseases165:376-80.
Bonnez et al. (1994) “Evaluation of Temperature Sensitivity of Human Papillomavirus Type 11 by Using the Human Xenograft Severe Combined Immu
Kirnbauer Reinhard
Lowy Douglas R.
Schiller John T.
Blumel Benjamin P.
Campell Bruce
Deutsches Krebsforschungszentrum, The German Cancer Research Cen
Knobbe Martens Olson & Bear LLP
The United States of America as represented by the Department of
LandOfFree
Self-assembling recombinant papillomavirus capsid proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Self-assembling recombinant papillomavirus capsid proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Self-assembling recombinant papillomavirus capsid proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3932209